中国免疫学杂志2025，Vol.41Issue(3)：727-732,6.DOI:10.3969/j.issn.1000-484X.2025.03.038
幽门螺杆菌对胃癌免疫检查点抑制剂疗效影响的研究进展
Research progress on effect of Helicobacter pylori on immune checkpoint inhibitors of gastric cancer
摘要
Abstract
Gastric cancer is a malignant tumor of the digestive system with strong invasiveness and a high metastasis rate.Its morbidity and mortality rank among the top five in the world and the prognosis is closely related to the disease stage.Multidisciplinary comprehensive treatment based on systemic antitumor drugs is generally adopted in patients with advanced or metastatic gastric can-cer,but the prognosis is typically poor.With the in-depth research on the tumor microenvironment,the development of multi-omics technology,and the application of immunotherapy and neoadjuvant chemoradiotherapy,the therapeutic effect of advanced gastric can-cer has been initially improved,and immunotherapy has become the most potential of the treatment strategies.Many studies have found that Helicobacter pylori(Hp)infection status is closely related to the efficacy of immunotherapy for gastric cancer,especially im-mune checkpoint inhibitors(ICIs),but there is not clear whether it has advantages or disadvantages.This article reviews the current research on the efficacy of Hp on ICIs in advanced gastric cancer to provide ideas for further research on the interaction between Hp in-fection and tumor immunotherapy.关键词
胃癌/幽门螺杆菌/免疫检查点抑制剂/PD-1/PD-L1/免疫治疗Key words
Gastric cancer/Helicobacter pylori/Immune checkpoint inhibitors/PD-1/PD-L1/Immunotherapy分类
医药卫生引用本文复制引用
李麻图,郑亚,赵进玉,舒小闯,李强,王玉平,周永宁..幽门螺杆菌对胃癌免疫检查点抑制剂疗效影响的研究进展[J].中国免疫学杂志,2025,41(3):727-732,6.基金项目
国家自然科学基金项目(71964021) （71964021）
兰州大学第一医院院内基金项目(ldyyyn2021-8,ldyyyn2021-59). （ldyyyn2021-8,ldyyyn2021-59）
